Onset Capital

Onset Capital targets the earliest stages of company formation — primarily pre-seed and seed rounds. The firm is structured to be a startup's first institutional investor, providing initial capital before a company has significant revenue or product-market fit. Follow-on investments are reserved for select portfolio companies that demonstrate strong early traction.

Onset concentrates on technology and life sciences. Within technology, its activity has historically centered on enterprise software, applied artificial intelligence, and data infrastructure. In life sciences, the firm has evaluated and backed biotechnology platforms and therapeutics companies at the earliest stages of development.

Yes. As an early-stage specialist, Onset typically leads or co-leads the initial financing rounds it participates in. Leading rounds allows the firm to set terms and governance structures that align with the intensive, hands-on partnership model it employs with founding teams.

Onset has historically maintained a concentrated portfolio, targeting a small number of new investments each year. This pace reflects a deliberate choice to offer deep operational engagement to each portfolio company rather than scaling through deal volume. Specific annual figures are not publicly disclosed.

Onset is headquartered in Palo Alto, and its investment activity is concentrated in Silicon Valley and the broader San Francisco Bay Area. While the firm may opportunistically back companies in other US technology hubs, its network, origination, and operational support model are built around proximity to Northern California's startup ecosystem.